<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Vigabatrin add‐on therapy for drug‐resistant focal epilepsy - Bresnahan, R - 2020 | Cochrane Library</title> <meta content="Vigabatrin add‐on therapy for drug‐resistant focal epilepsy - Bresnahan, R - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007302.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Vigabatrin add‐on therapy for drug‐resistant focal epilepsy - Bresnahan, R - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007302.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007302.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Vigabatrin add‐on therapy for drug‐resistant focal epilepsy" name="citation_title"/> <meta content="Rebecca Bresnahan" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="rebecca.bresnahan@liverpool.ac.uk" name="citation_author_email"/> <meta content="Myrsini Gianatsi" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Melissa J Maguire" name="citation_author"/> <meta content="Leeds General Infirmary" name="citation_author_institution"/> <meta content="Catrin Tudur Smith" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD007302.pub3" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/07/30" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007302.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007302.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007302.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [adverse effects, *therapeutic use]; Dizziness [chemically induced]; Drug Resistant Epilepsy [*drug therapy]; Drug Therapy, Combination; Epilepsies, Partial [*drug therapy]; Fatigue [chemically induced]; Nystagmus, Pathologic [chemically induced]; Randomized Controlled Trials as Topic; Seizures [drug therapy]; Vigabatrin [adverse effects, *therapeutic use]; Vision Disorders [chemically induced]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007302.pub3&amp;doi=10.1002/14651858.CD007302.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="IregKd2C";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007302\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007302\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ko","ms","ja","hr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007302.pub3",title:"Vigabatrin add\\u2010on therapy for drug\\u2010resistant focal epilepsy",firstPublishedDate:"Jul 30, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007302.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007302.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007302.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007302.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007302.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007302.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007302.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007302.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007302.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007302.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1723 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007302.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0063"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-sec-0057"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/appendices#CD007302-sec-0068"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/table_n/CD007302StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/table_n/CD007302StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Vigabatrin add‐on therapy for drug‐resistant focal epilepsy</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#CD007302-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Rebecca Bresnahan</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#CD007302-cr-0005">Myrsini Gianatsi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#CD007302-cr-0006">Melissa J Maguire</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#CD007302-cr-0007">Catrin Tudur Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information#CD007302-cr-0008">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information/en#CD007302-sec-0077">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 30 July 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007302.pub3">https://doi.org/10.1002/14651858.CD007302.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007302-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007302-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007302-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007302-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007302-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007302-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007302-abs-0001" lang="en"> <section id="CD007302-sec-0001"> <h3 class="title" id="CD007302-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane Review published in 2008 and updated in 2013. </p> <p>Epilepsy is a common neurological condition which affects up to 1% of the population. Approximately 30% of people with epilepsy do not respond to treatment with currently available drugs. The majority of these people have focal epilepsy. Vigabatrin is an antiepileptic drug licensed for use in drug‐resistant epilepsy. </p> </section> <section id="CD007302-sec-0002"> <h3 class="title" id="CD007302-sec-0002">Objectives</h3> <p>To assess the efficacy and tolerability of vigabatrin as an add‐on therapy for people with drug‐resistant focal epilepsy. </p> </section> <section id="CD007302-sec-0003"> <h3 class="title" id="CD007302-sec-0003">Search methods</h3> <p>For the latest update of this review, we searched the following databases on 1 November 2018: Cochrane Register of Studies (CRS Web), MEDLINE (Ovid 1946 to 31 October 2018), ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. The Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL) are both included in the Cochrane Register of Studies (CRS Web). We checked reference lists of retrieved studies for additional reports of relevant studies and contacted Hoechst Marion Roussel (manufacturers of vigabatrin) in 2000. </p> </section> <section id="CD007302-sec-0004"> <h3 class="title" id="CD007302-sec-0004">Selection criteria</h3> <p>We included randomised, double‐blind, placebo‐controlled, fully published trials of vigabatrin in people of any age with drug‐resistant focal epilepsy. </p> </section> <section id="CD007302-sec-0005"> <h3 class="title" id="CD007302-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed trials for inclusion and extracted data using the standard methodological procedures expected by Cochrane. Primary analysis was by intention‐to‐treat (ITT). We evaluated: 50% or greater reduction in seizure frequency, treatment withdrawal, adverse effects, dose‐response analysis, cognitive outcomes and quality of life. We presented results as risk ratios (RR) with 95% or 99% confidence intervals (CI). </p> </section> <section id="CD007302-sec-0006"> <h3 class="title" id="CD007302-sec-0006">Main results</h3> <p>We identified 11 trials that included 756 participants (age range: 10 to 64 years). The trials tested vigabatrin doses between 1 g/day and 6 g/day. All 11 trials displayed a risk of bias across at least three risk of bias domains. Predominantly, the risk of bias was associated with: allocation concealment (selection bias), blinding of outcome assessment (detection bias) and incomplete outcome data (attrition bias). </p> <p>Participants treated with vigabatrin may be two to three times more likely to obtain a 50% or greater reduction in seizure frequency compared with those treated with placebo (RR 2.60, 95% CI 1.87 to 3.63; 4 studies; low‐certainty evidence). Those treated with vigabatrin may also be three times more likely to have treatment withdrawn although we are uncertain (RR 2.86, 95% CI 1.25 to 6.55; 4 studies; very low‐certainty evidence). </p> <p>Compared to placebo, participants given vigabatrin were more likely to experience adverse effects: dizziness/light‐headedness (RR 1.74, 95% CI 1.05 to 2.87; 9 studies; low‐certainty evidence), fatigue (RR 1.65, 95% CI 1.08 to 2.51; 9 studies; low‐certainty evidence), drowsiness (RR 1.70, 95% CI 1.18 to 2.44; 8 studies) and depression (RR 3.28, 95% CI 1.30 to 8.27; 6 studies). </p> <p>Although the incidence rates were higher among participants receiving vigabatrin compared to those receiving placebo, the effect was not significant for the following adverse effects: ataxia (RR 2.76, 95% CI 0.96 to 7.94; 7 studies; very low‐certainty evidence), nausea (RR 3.57, 95% CI 0.63 to 20.30; 4 studies), abnormal vision (RR 1.64, 95% CI 0.67 to 4.02; 5 studies; very low‐certainty evidence), headache (RR 1.23, 95% CI 0.79 to 1.92; 9 studies), diplopia (RR 1.76, 99% CI 0.94 to 3.30) and nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; low‐certainty evidence). </p> <p>Vigabatrin had little to no effect on cognitive outcomes or quality of life.</p> </section> <section id="CD007302-sec-0007"> <h3 class="title" id="CD007302-sec-0007">Authors' conclusions</h3> <p>Vigabatrin may significantly reduce seizure frequency in people with drug‐resistant focal epilepsy. The results largely apply to adults and should not be extrapolated to children under 10 years old. Short‐term follow‐up of participants showed that some adverse effects were associated with its use. Analysis of longer‐term observational studies elsewhere, however, has demonstrated that vigabatrin use can lead to the development of visual field defects. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007302-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007302-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007302-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007302-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007302-abs-0010">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007302-abs-0009">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007302-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007302-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD007302-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007302-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007302-abs-0002" lang="en"> <h3>Vigabatrin add‐on for drug‐resistant focal epilepsy</h3> <p><b>Background</b> </p> <p>Epilepsy is a common neurological disorder affecting approximately 1 in 100 people. Around 30% of these people cannot control their epilepsy with currently available antiepileptic medication and are said to have drug‐resistant epilepsy. Most often, drug‐resistant epilepsy is focal in nature, meaning that the seizures start in one specific area of the brain. Vigabatrin is an antiepileptic medication that can be used as an add‐on treatment for drug‐resistant focal epilepsy, meaning that it is taken in addition to other antiepileptic medications. </p> <p><b>Main results</b> </p> <p>We found 11 clinical trials, involving 756 people, which investigated vigabatrin as an add‐on for people with drug‐resistant focal epilepsy. The people in the trials were aged between 10 to 64 years and were given doses of 1 g/day to 6 g/day vigabatrin. </p> <p>We found that people given vigabatrin may be two to three times more likely to experience a 50% or greater reduction in seizure frequency than people given placebo (a non‐active treatment). We also suggest that people given vigabatrin may be up to three times more likely to stop treatment than people given placebo. People given vigabatrin were more likely to experience side effects: dizziness/light‐headedness, fatigue, drowsiness and depression, than people given placebo. However, the evidence suggested that they should not be more likely to experience: ataxia (disorders that affect co‐ordination, balance and speech), feeling sick (nausea), abnormal vision, headache, seeing double (diplopia), or involuntary movement of the eyes (nystagmus) than people given placebo. </p> <p><b>Reliability of the evidence</b> </p> <p>We judged that all studies had significant risk of bias. The studies did not explain how people were allocated to treatment groups and did not say whether investigators knew which treatment people were receiving. Alongside other reasons, this reduced our confidence (certainty) in the results. Overall, we are uncertain to very uncertain whether the results we have reported are reliable. The true effect of vigabatrin could be significantly different to that reported here. </p> <p><b>Conclusions</b> </p> <p>Vigabatrin may significantly reduce seizure frequency for people with drug‐resistant focal epilepsy but we are uncertain. Most of the evidence was gathered from adults, therefore, the effects of vigabatrin could be different in children. All of the included trials were of short duration; therefore, we cannot report any long‐term effects of vigabatrin. Importantly, reviews of long‐term studies have reported that long‐term vigabatrin use can lead to the development of visual problems. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007302-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007302-sec-0063"></div> <h3 class="title" id="CD007302-sec-0064">Implications for practice</h3> <section id="CD007302-sec-0064"> <p>When used as an add‐on for people with drug‐resistant focal epilepsy, vigabatrin may significantly reduce seizure frequency. Add‐on vigabatrin may also cause more people to withdraw from treatment. Although not reported here, work by others has shown that long‐term vigabatrin is associated with visual field constrictions which occur in a significant number of people taking vigabatrin. We suggest that we were unable to detect these visual adverse effects because of their asymptomatic presentation and due to the short duration of RCTs. Given the seriousness of such visual adverse effects, the implications of long‐term vigabatrin use should still be considered before commencing vigabatrin add‐on therapy. </p> </section> <h3 class="title" id="CD007302-sec-0065">Implications for research</h3> <section id="CD007302-sec-0065"> <p>Further research is required to identify the risk of visual field defects and those who are susceptible to it. Further randomised controlled trials are also necessary to examine the efficacy and tolerability of add‐on vigabatrin in children with drug‐resistant focal epilepsy, as well as comparing the efficacy of add‐on vigabatrin to using other antiepileptic medications as add‐on therapies. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007302-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007302-sec-0008"></div> <div class="table" id="CD007302-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vigabatrin compared to placebo for drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vigabatrin compared to placebo for drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people (aged 10–64 years) with drug‐resistant focal epilepsy </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> vigabatrin (doses used: 2 g/day, 3 g/day, 1–4 g/day, 6 g/day) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI, 99% CI for adverse effect outcomes)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI, 99% CI for adverse effect outcomes)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vigabatrin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ <b>50% reduction in seizure frequency (ITT analysis)</b> </p> <p>Duration of treatment (range): 16–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.60</b><br/>(1.87 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>513</b><br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The other 7 studies did report the outcome; however, the data were not usable. The studies compared seizure frequency with vigabatrin to the placebo treatment period rather than the baseline period, as per our definition. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>468 per 1000<br/>(337 to 654) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal for any reason</b> </p> <p>Duration of treatment (range): 12 (3 months) to 36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.86</b><br/>(1.25 to 6.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>370</b><br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000<br/>(38 to 199) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: ataxia</b> </p> <p>Duration of treatment (range): 7–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.76</b><br/>(0.96 to 7.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>481</b><br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(13 to 108) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: dizziness/light‐headedness</b> </p> <p>Duration of treatment (range): 7–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.74</b><br/>(1.05 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>709</b><br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/>(88 to 240) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: fatigue</b> </p> <p>Duration of treatment (range): 8–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.65</b><br/>(1.08 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>709</b><br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000<br/>(122 to 284) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: nystagmus</b> </p> <p>Duration of treatment (range): 16–18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.53</b><br/>(0.62 to 3.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>357</b><br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>L<b>ow</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/>(55 to 334) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: abnormal vision</b> </p> <p>Duration of treatment (range): 8–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.64</b><br/>(0.67 to 4.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>430</b><br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(30 to 182) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ITT:</b> intention‐to‐treat; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias. We judged all included studies at unclear risk of bias for allocation concealment and blinding of outcome assessment. Furthermore, we assessed most studies at unclear risk of selection bias and attrition bias with three studies displaying high risk of selection bias.<br/><sup>b</sup>Downgraded one level for imprecision: the number of events (fewer than 400) did not satisfy the optimal information size.<br/><sup>c</sup>Downgraded two levels for imprecision: the number of events (fewer than 100) did not satisfy the optimal information size. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007302-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007302-sec-0009"></div> <section id="CD007302-sec-0010"> <h3 class="title" id="CD007302-sec-0010">Description of the condition</h3> <p>Epilepsy is a common neurological condition with an estimated incidence of 61.4 per 100,000 person‐years and a global lifetime‐prevalence of 7.6 per 1000 (<a href="./references#CD007302-bbs2-0021" title="Fiest KirstenM , Sauro KharaM , Wiebe Samuel, Patten ScottB , Kwon Churl-Su, Dykeman Jonathan, et al. Prevalence and incidence of epilepsy: A systematic review and meta-analysis of international studies. Neurology2017;88(3):296-303.">Fiest 2017</a>). While the majority of people who are diagnosed with epilepsy will go into remission, up to 30% will develop drug‐resistant epilepsy despite treatment with combinations of antiepileptic drugs (AEDs) (<a href="./references#CD007302-bbs2-0019" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the national general practice study of epilepsy. Lancet1995;346:140-4.">Cockerell 1995</a>). The majority of people who are resistant to drug treatment have localised related seizures, commonly known as focal seizures. These are divided into the three types: focal aware, focal impaired‐awareness and secondarily generalised tonic‐clonic seizures (<a href="./references#CD007302-bbs2-0022" title="Fisher RobertS , Cross J Helen, French JacquelineA , Higurashi Norimichi, Hirsch Edouard, Jansen FloorE , et al. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia2017;58(4):522-30. [DOI: 10.111/epi.13670]">Fisher 2017</a>). </p> </section> <section id="CD007302-sec-0011"> <h3 class="title" id="CD007302-sec-0011">Description of the intervention</h3> <p>Since 1993, numerous second‐generation AEDs have been licensed for use as add‐on therapy in drug‐resistant epilepsy (<a href="./references#CD007302-bbs2-0017" title="ChungAM , EilandLS . Use of second-generation antiepileptic drugs in the pediatric population. Paediatric drugs2008;10(4):217-54. [PMID: 18590343]">Chung 2008</a>). One of the earliest second‐generation drugs to be approved for use was vigabatrin (vinyl‐GABA or VGB). Vigabatrin was initially licensed in 1989 as add‐on therapy for adults with drug‐resistant focal epilepsy and was considered an efficacious treatment (<a href="./references#CD007302-bbs2-0030" title="MarsonAG , KadirZA , ChadwickDW . New antiepileptic drugs: a systematic review of their efficacy and tolerability. British Medical Journal1996;313(7066):1169-74.">Marson 1996</a>). In 1997, concerns were first raised about visual field constrictions observed in people taking vigabatrin (<a href="./references#CD007302-bbs2-0020" title="EkeT , TalbotJF , LawdenMC . Severe persistent visual field constriction associated with vigabatrin. British Medical Journal1997;314(7075):180-1.">Eke 1997</a>). Since these initial concerns were raised, numerous observational studies have investigated the prevalence of visual field constrictions in people taking vigabatrin. In one systematic review of 1678 people taking vigabatrin, 44% had visual field loss compared to just 7% of the 406 people taking a control (<a href="./references#CD007302-bbs2-0029" title="MaguireMJ , HemmingK , WildJM , HuttonJL , MarsonAG . Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia2010;51(12):2423-31. [DOI: 10.1111/j.1528-1167.2010.02772]">Maguire 2010</a>). One large longitudinal study of 563 people, of whom 432 were tested, found 31% of those aged eight to 12 years and 42% of those older than 12 years had a visual field defect; risks increased with exposure duration and increased mean dose (<a href="./references#CD007302-bbs2-0037" title="WildJM , AhnHS , BaulacM , BursztrynJ , ChrionC , GandolfoE , et al. Vigabatrin and epilepsy: lessons learned. Epilepsia2007;48:1318-27.">Wild 2007</a>). </p> </section> <section id="CD007302-sec-0012"> <h3 class="title" id="CD007302-sec-0012">How the intervention might work</h3> <p>Vigabatrin is a structural analogue of gamma‐aminobutyric acid (GABA), which irreversibly inhibits GABA‐transaminase (<a href="./references#CD007302-bbs2-0024" title="GrantSM , HeelRC . Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs1991;41(6):889-926. [PMID: 1715266]">Grant 1991</a>), and increases brain levels of the inhibitory transmitter GABA (<a href="./references#CD007302-bbs2-0033" title="SchechterPJ , HankeNF , GroveJ , HuebertN , SjoerdsmaA . Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology1984;34(2):182-6. [PMID: 6538006]">Schechter 1984</a>). </p> </section> <section id="CD007302-sec-0013"> <h3 class="title" id="CD007302-sec-0013">Why it is important to do this review</h3> <p>Vigabatrin is also used in the treatment of infantile spasms (West syndrome), particularly when associated with tuberous sclerosis (<a href="./references#CD007302-bbs2-0025" title="HancockEC , OsborneJP , EdwardsSW . Treatment of infantile spasms. Cochrane Database of Systematic Reviews2008, Issue 4. Art. No: CD001770. [DOI: 10.1002/14651858.CD001770.pub2]">Hancock 2008</a>; <a href="./references#CD007302-bbs2-0036" title="WhelessJW , ClarkeDF , CarpenterD . Treatment of pediatric epilepsy: expert opinion. Journal of Child Neurology2005;20 Suppl:1-56.">Wheless 2005</a>). However, as this review focuses on the use of vigabatrin in drug‐resistant focal epilepsy, neither its efficacy nor tolerability is investigated here for the treatment of infantile spasms, tuberous sclerosis or West syndrome. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007302-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007302-sec-0014"></div> <p>To assess the efficacy and tolerability of vigabatrin as an add‐on therapy for people with drug‐resistant focal epilepsy. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007302-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007302-sec-0015"></div> <section id="CD007302-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007302-sec-0017"> <h4 class="title">Types of studies</h4> <p>Studies had to meet all of the following criteria:</p> <p> <ol id="CD007302-list-0001"> <li> <p>randomised controlled trial (RCT);</p> </li> <li> <p>double‐blinded;</p> </li> <li> <p>placebo‐controlled;</p> </li> <li> <p>parallel‐group or cross‐over design.</p> </li> </ol> </p> </section> <section id="CD007302-sec-0018"> <h4 class="title">Types of participants</h4> <p>People of any age with drug‐resistant focal epilepsy (that is, experiencing focal aware, focal impaired‐awareness or secondary generalised tonic‐clonic seizures). We did not consider the treatment of people with infantile spasms, tuberous sclerosis or West syndrome in this review. </p> </section> <section id="CD007302-sec-0019"> <h4 class="title">Types of interventions</h4> <p> <ol id="CD007302-list-0002"> <li> <p>Active treatment group: vigabatrin in addition to an existing AED regimen being taken at the time of randomisation. </p> </li> <li> <p>Control group: matched placebo in addition to an existing AED regimen being taken at the time of randomisation. </p> </li> </ol> </p> </section> <section id="CD007302-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD007302-sec-0021"> <h5 class="title">Primary outcome</h5> <p> <ol id="CD007302-list-0003"> <li> <p><b>50% or greater reduction in seizure frequency:</b> we chose the proportion of participants with a 50% or greater reduction in seizure frequency as the measure of treatment efficacy. The seizure frequency during the treatment period was compared to the prerandomisation baseline period. This outcome was chosen as it is commonly reported in this type of study. </p> </li> </ol> </p> </section> <section id="CD007302-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD007302-list-0004"> <li> <p><b>Treatment withdrawal for any reason:</b> we chose the proportion of participants having treatment withdrawn during the course of the treatment period as a measure of global effectiveness. Treatment may be withdrawn due to adverse effects, lack of efficacy, a combination of both, or sometimes due to other reasons unrelated to treatment. However, in studies of relatively short duration, such as the studies included here, adverse effects are likely to be the main reason for treatment withdrawal. </p> </li> <li> <p><b>Adverse effects:</b> </p> <ol id="CD007302-list-0005"> <li> <p>the proportion of participants experiencing any of the following five adverse effects that are considered by the review authors to be common and important adverse effects of AEDs: </p> <ol id="CD007302-list-0006"> <li> <p>ataxia (co‐ordination problems);</p> </li> <li> <p>dizziness or light headedness;</p> </li> <li> <p>fatigue or drowsiness;</p> </li> <li> <p>nausea;</p> </li> <li> <p>depression;</p> </li> </ol> </li> <li> <p>vigabatrin has a known association with visual field defects. In this review of short‐term RCTs, it was not possible to identify associated visual field constrictions as they are often asymptomatic. The association with long‐term visual field constrictions is the subject of another systematic review (<a href="./references#CD007302-bbs2-0029" title="MaguireMJ , HemmingK , WildJM , HuttonJL , MarsonAG . Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia2010;51(12):2423-31. [DOI: 10.1111/j.1528-1167.2010.02772]">Maguire 2010</a>). Therefore, we instead assessed the proportion of participants experiencing the following visual adverse effects which could be detected within the time course of the studies: </p> <ol id="CD007302-list-0007"> <li> <p>abnormal vision;</p> </li> <li> <p>diplopia (double vision);</p> </li> <li> <p>nystagmus (involuntary eye movement).</p> </li> </ol> </li> </ol> </li> <li> <p><b>Dose‐response analysis:</b> we evaluated the proportion of participants experiencing a 50% or greater reduction in seizure frequency by dose of the drug. </p> </li> <li> <p><b>Cognitive outcomes and quality of life:</b> there is no consensus on which instruments should be used to assess the effects of AEDs on cognition and quality of life outcomes (<a href="./references#CD007302-bbs2-0018" title="CochraneHC , MarsonAG , BakerGA , ChadwickDW . Neuropsychological outcomes in randomised controlled trial of antiepileptic drugs. A systematic review of methodology and reporting standards. Epilepsia1998;39(10):1088-97.">Cochrane 1998</a>). Due to this, we provided a simple descriptive summary of findings of the effects of vigabatrin on cognitive and quality of life outcomes. We did not synthesise results in a meta‐analysis. </p> </li> </ol> </p> </section> </section> </section> <section id="CD007302-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007302-sec-0024"> <h4 class="title">Electronic searches</h4> <p>This search was run for the original review in March 2008 and subsequent searches on 25 October 2010, 12 October 2012 and 4 February 2014. For the most recent update of this review, we searched the following databases on 1 November 2018: </p> <p> <ol id="CD007302-list-0008"> <li> <p>Cochrane Register of Studies (CRS Web) using the search strategy set out in <a href="./appendices#CD007302-sec-0069">Appendix 1</a>; </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 31 October 2018) using the search strategy set out in <a href="./appendices#CD007302-sec-0070">Appendix 2</a>; </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>) using the search strategy set out in <a href="./appendices#CD007302-sec-0071">Appendix 3</a>; </p> </li> <li> <p>World Health Organization (WHO) International Clinical Trials Registry Platform (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) using the search strategy set out in <a href="./appendices#CD007302-sec-0072">Appendix 4</a>. </p> </li> </ol> </p> <p>The Cochrane Epilepsy Group Specialized Register and the Cochrane Central Register of Controlled Trials (CENTRAL) are included in CRS Web. </p> <p>The search strategies used for the earlier version of this review are set out in <a href="./appendices#CD007302-sec-0073">Appendix 5</a>. </p> </section> <section id="CD007302-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of retrieved studies for additional reports of relevant studies. </p> <p>We contacted the manufacturers of vigabatrin, Hoechst Marion Roussel, in 2000 requesting information about any unpublished or ongoing studies. The company has since rebranded as Sanofi. We contacted Sanofi, again requesting information regarding any unpublished or ongoing studies, during the most recent literature search in 2018. </p> <p>We included only fully published and peer‐reviewed studies. We imposed no language restrictions. </p> </section> </section> <section id="CD007302-sec-0026"> <h3 class="title" id="CD007302-sec-0026">Data collection and analysis</h3> <section id="CD007302-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Two review authors (RB and MG) independently assessed trials for inclusion and extracted information from the trials. Any disagreements were resolved by discussion. </p> </section> <section id="CD007302-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following information from the included trials.</p> <p> <ol id="CD007302-list-0009"> <li> <p><b>Methodological and trial design</b> </p> <ol id="CD007302-list-0010"> <li> <p>Method of randomisation concealment (e.g. allocation of sequentially sealed packages of medication, sealed opaque envelopes, telephone randomisation). </p> </li> <li> <p>Method of blinding.</p> </li> <li> <p>Whether any participants had been excluded from the reported analyses.</p> </li> <li> <p>Duration of baseline period.</p> </li> <li> <p>Duration of treatment period.</p> </li> <li> <p>Duration of any washout period.</p> </li> <li> <p>Dose(s) of vigabatrin tested.</p> </li> </ol> </li> <li> <p><b>Participant, demographic information</b> </p> <ol id="CD007302-list-0011"> <li> <p>Total number of participants allocated to each treatment group.</p> </li> <li> <p>Age range and number of each sex.</p> </li> <li> <p>Types of epilepsy or seizure types.</p> </li> <li> <p>Number of concomitant AEDs.</p> </li> </ol> </li> <li> <p><b>Outcomes</b> </p> <ol id="CD007302-list-0012"> <li> <p>We recorded the number of participants experiencing each outcome (see <a href="#CD007302-sec-0020">Types of outcome measures</a>) per randomised group. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD007302-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (RB and MG) independently assessed risk of bias for each trial using the Cochrane 'Risk of bias' tool as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD007302-bbs2-0027" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011</a>). We discussed and resolved any disagreements. We judged the studies at high, low or unclear risk of bias across six chosen domains: random sequence generation, allocation concealment, blinding of participants and study personnel, blinding of outcome assessment, incomplete outcome data, selective outcome reporting and other sources of bias. </p> </section> <section id="CD007302-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We synthesised data using the risk ratio (RR). For the outcomes 50% reduction in seizure frequency and treatment withdrawal, we have quoted 95% confidence intervals (CIs). For individual adverse effects, we quoted 99% CIs to make an allowance for multiple testing. We did not use RR for cognitive or quality of life outcomes because we instead narratively synthesised the evidence for these outcomes. We had intended to evaluate dose‐response relationships using a regression model; however, only two trials provided data that could be used to evaluate this outcome. Therefore, we found it necessary to partake a narrative synthesis for this outcome. </p> </section> <section id="CD007302-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>For the cross‐over trials, we used data from both periods and assumed that there was no carry‐over effect. Ideally, we would have only included data from the first treatment period to replicate a parallel‐study design, however, the data were largely unavailable with only one trial providing fully paired data. The other cross‐over trials provided no information on paired responses, and only the total number of responders under either treatment or placebo was available. In such cases, it is possible to calculate the RR estimate but not possible to calculate the exact estimate for the variance of the RR. To avoid excluding such trials, we calculated an approximate estimate of the variance of the RR, assuming independence between outcomes under placebo and vigabatrin. This approximate estimate is an overestimate and, therefore, may be regarded as a more conservative estimate. For the one trial which did provide fully paired information, the approximate estimate was similar to the exact estimate of variance in the paired analysis. In essence, the extra information of knowing that the sample receiving the placebo was the same sample as those receiving the treatment would improve our analysis. However, due to the way that the trials reported results, this information was not available. </p> <p>Participants randomised to cross‐over trials, therefore, contributed two observations. The first observation consisted of their responder status under placebo and the second observation consisted of their responder status under the intervention drug, vigabatrin. The terms 'participants' and 'observations' have been used to distinguish these differences. </p> </section> <section id="CD007302-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>All analyses included all participants in the treatment groups to which they had been allocated. For the efficacy outcome (50% or greater reduction in seizure frequency), we undertook the following analyses (two of which were sensitivity analyses). </p> <p> <ol id="CD007302-list-0013"> <li> <p>Primary (ITT) analysis: participants from both treatment groups (vigabatrin or placebo) not completing follow‐up or with inadequate seizure data were assumed to be non‐responders. </p> <ol id="CD007302-list-0014"> <li> <p>Worst‐case analysis (sensitivity analysis): participants not completing follow‐up or with inadequate seizure data were assumed to be non‐responders in the intervention (vigabatrin) group, but were assumed to be responders in the placebo group. </p> </li> <li> <p>Best‐case analysis (sensitivity analysis): participants not completing follow‐up or with inadequate seizure data were assumed to be responders in the intervention (vigabatrin) group, but were assumed to be non‐responders in the placebo group. </p> </li> </ol> </li> </ol> </p> </section> <section id="CD007302-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by comparing the distribution of important participant factors between trials (age, seizure type, duration of epilepsy, number of AEDs taken at time of randomisation) and trial factors (randomisation concealment, blinding, losses to follow‐up). </p> <p>We assessed statistical heterogeneity by using the I<sup>2</sup> statistic, with an I<sup>2</sup> greater than 50% indicating significant heterogeneity. We found statistical heterogeneity to be present for several outcomes. Where results differed between choice of model, we presented results based on both fixed‐effect and random‐effects models. </p> </section> <section id="CD007302-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess any possible small‐study effect bias, we had planned to create a funnel plot by plotting the RR against the standard error of the RR. Unfortunately, due to the limited number of studies that reported each outcome (fewer than 10 studies), we were unable to construct a funnel plot, in accordance with Cochrane guidelines (<a href="./references#CD007302-bbs2-0035" title="SterneJA , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Sterne 2011</a>). </p> </section> <section id="CD007302-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We undertook analyses using Review Manager 5, the Cochrane software package (<a href="./references#CD007302-bbs2-0032" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Our preferred effect estimator for calculating the RR was the Mantel‐Haenszel method. In the case that no clinical or statistical heterogeneity (I<sup>2</sup> of 50% or less) was detected, we used a fixed‐effect model. In contrast, when there was either clinical or statistical heterogeneity (I<sup>2</sup> greater than 50%), we utilised a random‐effects model for the meta‐analysis. </p> <p>Due to the reporting methods of the original trial articles, we had to make some approximations when calculating the effect estimates. In all cases, any approximation made was conservative. That is, it was more in favour of a greater efficacy of the placebo than vigabatrin. We have detailed these approximations in the <a href="#CD007302-sec-0031">Unit of analysis issues</a> section. </p> </section> <section id="CD007302-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We completed subgroup analysis according to the participant factor or trial factor identified as, or suspected of, producing any clinical heterogeneity detected during meta‐analysis. </p> </section> <section id="CD007302-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>We employed a sensitivity analysis for the efficacy outcome, 50% or greater reduction in seizure frequency, whereby we completed a best‐ and worst‐case ITT analysis (described in <a href="#CD007302-sec-0032">Dealing with missing data</a>). We also carried out a sensitivity analysis to determine whether the differences between a random‐effects model and fixed‐effect model influenced the conclusions drawn. </p> </section> <section id="CD007302-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We used the GRADE approach, as outlined in the <i>Handbook for Grading the Quality of Evidence and the Strength of Recommendations using the GRADE approach</i> (<a href="./references#CD007302-bbs2-0034" title="SchünemannH , BrożekJ , GuyattG , OxmanA , editor(s) GRADE Working Group. Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). Available from guidelinedevelopment.org/handbook.">Schünemann 2013</a>), to assess the certainty of evidence and to interpret the review findings. We used GRADEpro GDT software (<a href="./references#CD007302-bbs2-0023" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed 6 January 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), 2015. Available at gradepro.org.">GRADEpro GDT 2015</a>), which imports data from Review Manager 5 (<a href="./references#CD007302-bbs2-0032" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>), to create a 'Summary of findings' table for the following outcomes: 50% or greater reduction in seizure frequency, treatment withdrawal for any reason, ataxia, dizziness or light‐headedness, fatigue or drowsiness, abnormal vision and nystagmus. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007302-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007302-sec-0039"></div> <section id="CD007302-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD007302-sec-0041"> <h4 class="title">Results of the search</h4> <p>The results for all searches, collated, are available in <a href="#CD007302-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD007302-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007302-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>The searches conducted in March 2008 and October 2010 identified 58 records through MEDLINE, 202 records through CENTRAL and 122 records through the Cochrane Epilepsy Group Specialised Register. Removing obvious duplicates and irrelevant records from the identified records resulted screening of 149 records. Detailed checks of the abstracts of these 149 records resulted in the exclusion of eight records which referred to single‐blinded studies, 62 records which were conference proceedings, 21 records which related to the treatment of infantile spasms or other syndromes, five records which were head‐to‐head trials, and 17 records which studied visual field defects. A further six records had no efficacy data available, six records were not placebo‐controlled and five records were long‐term follow‐up studies. </p> <p>We consequently screened 19 records at the full‐text stage. We determined that 14 records, related to 11 individual studies were eligible for inclusion in this review (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). The other five records were excluded at the full‐text stage for reasons described in <a href="#CD007302-sec-0044">Excluded studies</a> (<a href="./references#CD007302-bbs2-0012" title="ChironC , DulacO , MumfordJ . Vigabatrin withdrawal randomised study in children. Epilepsy Research1996;25:209-15. ">Chiron 1996</a>; <a href="./references#CD007302-bbs2-0013" title="ProvincialiL , BartoliniM , MariF , Del PesceM , CeravoloMG . Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurologica Scandinavica1996;94:12-8. ">Provinciali 1996</a>; <a href="./references#CD007302-bbs2-0014" title="ReynoldsEH , RingHA , FarrIN , HellerAJ , ElwesRD . Open, double blind and long term study of vigabatrin in chronic epilepsy. Epilepsia1991;32:530-8. ">Reynolds 1991</a>; <a href="./references#CD007302-bbs2-0015" title="RingHA , FarrIN , ReynoldsEH . Vigabatrin: rational treatment for chronic epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1990;53:1051-5. ">Ring 1990</a>; <a href="./references#CD007302-bbs2-0016" title="ZahnerB , StefanH , BlankenhornV , KramerG , RichensA , ThumlerR , et al. Once-daily versus twice daily vigabatrin: is there a difference? The results of a double blind pilot study. Epilepsia1999;40:311-5. ">Zahner 1999</a>). </p> <p>We updated our searches in October 2012 and identified 12 records from MEDLINE and two records from CENTRAL. After removing duplicates and irrelevant records, we found no new studies for inclusion in this review. </p> <p>Similarly, we updated our searches in February 2014 and identified a further 21 records. Following the removal of duplicates and obviously irrelevant records, we found no new studies for inclusion in this review. </p> <p>In November 2018, we updated our searches and we identified 46 records. After removing duplicates and obviously irrelevant records, we screened 14 records at the abstract stage. We found no new studies that were eligible for inclusion in this review update. Of the 14 records that were excluded at the abstract stage: eight records were either literature reviews, meta‐analyses or involved pooled data; five records referred to studies that were not RCTs and one record referred to an active‐controlled trial. </p> </section> <section id="CD007302-sec-0042"> <h4 class="title">Included studies</h4> <p>We found 11 randomised, placebo‐controlled, double‐blind studies of vigabatrin as an add‐on treatment in drug‐resistant focal epilepsy, which reported on the primary efficacy outcome and met the inclusion criteria (see <a href="./references#CD007302-sec-0083" title="">Characteristics of included studies</a> table). Four of these trials were parallel‐group studies (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>), and seven were cross‐over trials (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). The 11 trials randomised 756 participants, with the vast majority of participants having focal epilepsy. For some of the outcomes, it was possible to exclude participants with seizures other than focal types but for some outcomes, due to the way results were reported in the original reports, this was not possible. For this reason, the number of participants contributing to the various outcomes differed. All participants had treatment‐resistant epilepsy and were taking between one and four concomitant AEDs. </p> <p><a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a> was an Australian multicentre, cross‐over study in 1996 on 97 participants under double‐blind conditions. Inclusion criteria were defined as participants aged 16 to 65 years with uncontrolled focal seizures. Treatment arms included 2 g/day or 3 g/day of vigabatrin and two placebo arms (2 g/day and 3 g/day placebo). After a run‐in period of eight weeks, participants were randomised to one of the four treatment arms for a treatment period of eight weeks. Participants then entered a washout period, where doses of vigabatrin were titrated down over a period of four weeks. At the end of the four‐week washout period, participants were crossed over to the matching treatment arm, which was followed by a further four‐week washout period. 80 participants were included in the reported analysis. </p> <p><a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a> was a randomised, double‐blind, placebo‐controlled, parallel‐group Canadian multicentre study in 2000 with 111 participants, aged between 18 and 50 years. After a baseline assessment period of 12 weeks, participants were randomised to one of two treatment arms and entered a 32‐week titration period, followed by a maintenance period lasting a further four weeks. Final daily doses of vigabatrin were between 1 g and 4 g. Of the 111 participants, 11 were excluded from the primary efficacy analysis due to major protocol violations. </p> <p><a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> reported a randomised, double‐blind, placebo‐controlled US multicentre, parallel‐group study with 174 participants aged between 18 and 63 years. There were four treatment arms: placebo and 1 g/day, 3 g/day and 6 g/day of vigabatrin. After a baseline assessment period of 12 weeks, participants were randomised to one of four treatment arms, and entered a six‐week titration period, followed by a further maintenance period lasting 12 weeks. </p> <p><a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a> reported a randomised, double‐blind, placebo‐controlled, parallel‐group study in 1996 with 183 participants. Participants were randomised to one of two treatment arms consisting of a placebo or 3 g/day of vigabatrin. Randomised participants were aged 18 to 60 years with drug‐resistant focal impaired‐awareness seizures with or without secondary generalisation. After a 12‐week baseline period, participants entered a four‐week titration period followed by a 12‐week maintenance period. Follow‐up during the maintenance period was at two, four, eight and 12 weeks. </p> <p><a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a> reported a randomised, double‐blind, placebo‐controlled, cross‐over trial with 21 participants aged between 17 and 63 years, all with focal epilepsy. Participants were randomised to one of two treatment arms, placebo or 3 g/day of vigabatrin, for 12 weeks and then crossed over to the other treatment arm for a further 12 weeks without a washout period. A final single‐blind placebo period was incorporated to test for any carry‐over effect. Only the last eight weeks of the treatment period were included in the analysis to incorporate a four‐week washout period. Participants were followed up every fourth week during the treatment phases. </p> <p><a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a> reported a randomised, double‐blind, placebo‐controlled, parallel‐group study based in the UK. A total of 45 participants, aged between 15 and 61 years, were randomised to one of two treatment arms, either placebo or 3 g/day of vigabatrin. Participants initially entered an eight‐week baseline period followed by a two‐week titration period and then an 18‐week maintenance period. </p> <p><a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a> reported a randomised, double‐blind, placebo‐controlled, cross‐over study with 23 participants randomised to either placebo or 3 g/day of vigabatrin. Participants were aged between 10 and 58 years. Of the 23 randomised participants, four had seizure types other than focal epilepsy and were excluded from all primary outcome results in this review. After a five‐week baseline period, participants were randomised to one of the two treatment arms for 10 weeks. Participants were then crossed over to the other treatment arm for a further 10 weeks without undergoing a washout period. The study was followed by a final five‐week, single‐blind placebo arm to evaluate any carry‐over effect, and one week from each treatment period was excluded from the analysis to incorporate a one‐week washout period. Participants were followed up every fifth week during the treatment phases. Four participants dropped out of the trial, two of whom had focal epilepsy. </p> <p><a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a> reported a randomised, double‐blind, placebo‐controlled, cross‐over study with 24 participants, aged between 17 and 53 years, who were randomised to either placebo or 3 g/day of vigabatrin. After a baseline period of four weeks, participants were randomised to one of the two treatment arms for 12 weeks followed by a four‐week washout period after which participants were crossed over to the other treatment arm for a further 12 weeks. Of the 24 participants, two had generalised tonic‐clonic epilepsy and, due to the way in which results were reported, had to be included in the analysis within this review. Participants were followed up at two, six and 12 weeks of treatment. Two participants had incomplete seizure data. </p> <p><a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a> reported a randomised, double‐blind, placebo‐controlled, cross‐over study with 24 participants, aged between 16 and 61 years, who were randomised to either placebo or 3 g/day of vigabatrin. After a baseline period of four weeks, participants were randomised to one of the two treatment arms for nine weeks. After the first treatment, participants were crossed over to the other treatment arm for a further nine weeks without a washout period. The 24 participants were reported to have 'mainly' focal impaired‐awareness epilepsy, and so it was possible that a small proportion of the study population may not have had focal epilepsy. </p> <p><a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a> reported a randomised, double‐blind, placebo‐controlled, cross‐over Italian study with 23 participants, aged between 17 and 50 years, who were randomised to either placebo or 2 g/day or 3 g/day of vigabatrin (dose dependent on bodyweight). Participants were randomised to one of the two treatment arms for seven weeks. After the first treatment, participants did not undergo a washout period but were immediately crossed over to the other treatment arm for a further seven weeks. The study included 23 participants, three of whom had seizure types other than focal epilepsy and who were excluded from all primary outcome results. Participants were followed up at two, four and seven weeks of treatment. </p> <p><a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a> reported a randomised, double‐blind, placebo‐controlled, cross‐over Italian study with 31 participants, aged between 10 and 58 years, who were randomised to either placebo or 2 g/day or 3 g/day dose of vigabatrin (dose dependent on bodyweight). After a baseline period of two months, participants were randomised to one of the two treatment arms for three months. Participants were then crossed over to the other treatment arm for a further three months without a washout period. The study included 31 participants, one of whom had progressive myoclonic epilepsy and was excluded from all primary outcome results. Participants were followed up every six weeks during the treatment phases. </p> </section> <section id="CD007302-sec-0043"> <h4 class="title">Clinical heterogeneity</h4> <p>All 11 trials were similar in both the age range and types of epilepsies included. Five trials included participants treated with two or fewer concomitant AEDs (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>); five trials included participants treated with three or fewer concomitant AEDs (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>); and one trial included participants treated with up to four concomitant AEDs (<a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). A sensitivity analysis (not shown) revealed no significant departures in primary efficacy outcomes between trials of participants with one or two concomitant AEDs compared to trials of participants with three or more concomitant AEDs. Where information on duration of epilepsy was provided, there were no significant differences in the ranges of duration of epilepsy between the trials (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>). </p> </section> <section id="CD007302-sec-0044"> <h4 class="title">Excluded studies</h4> <p>We excluded five studies at the full‐text screening stage (<a href="./references#CD007302-bbs2-0012" title="ChironC , DulacO , MumfordJ . Vigabatrin withdrawal randomised study in children. Epilepsy Research1996;25:209-15. ">Chiron 1996</a>; <a href="./references#CD007302-bbs2-0013" title="ProvincialiL , BartoliniM , MariF , Del PesceM , CeravoloMG . Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurologica Scandinavica1996;94:12-8. ">Provinciali 1996</a>; <a href="./references#CD007302-bbs2-0014" title="ReynoldsEH , RingHA , FarrIN , HellerAJ , ElwesRD . Open, double blind and long term study of vigabatrin in chronic epilepsy. Epilepsia1991;32:530-8. ">Reynolds 1991</a>; <a href="./references#CD007302-bbs2-0015" title="RingHA , FarrIN , ReynoldsEH . Vigabatrin: rational treatment for chronic epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1990;53:1051-5. ">Ring 1990</a>; <a href="./references#CD007302-bbs2-0016" title="ZahnerB , StefanH , BlankenhornV , KramerG , RichensA , ThumlerR , et al. Once-daily versus twice daily vigabatrin: is there a difference? The results of a double blind pilot study. Epilepsia1999;40:311-5. ">Zahner 1999</a>; see <a href="./references#CD007302-sec-0084" title="">Characteristics of excluded studies</a> table). Specifically, we excluded four trials that used a response‐conditional design (<a href="./references#CD007302-bbs2-0012" title="ChironC , DulacO , MumfordJ . Vigabatrin withdrawal randomised study in children. Epilepsy Research1996;25:209-15. ">Chiron 1996</a>; <a href="./references#CD007302-bbs2-0014" title="ReynoldsEH , RingHA , FarrIN , HellerAJ , ElwesRD . Open, double blind and long term study of vigabatrin in chronic epilepsy. Epilepsia1991;32:530-8. ">Reynolds 1991</a>; <a href="./references#CD007302-bbs2-0015" title="RingHA , FarrIN , ReynoldsEH . Vigabatrin: rational treatment for chronic epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1990;53:1051-5. ">Ring 1990</a>; <a href="./references#CD007302-bbs2-0016" title="ZahnerB , StefanH , BlankenhornV , KramerG , RichensA , ThumlerR , et al. Once-daily versus twice daily vigabatrin: is there a difference? The results of a double blind pilot study. Epilepsia1999;40:311-5. ">Zahner 1999</a>). In these trials, participants were randomised to either vigabatrin or placebo under the condition that they had demonstrated a response to vigabatrin in an earlier, baseline phase of the trial. We subsequently identified one study as being single‐blinded, although this had not been stated in the article abstract or title, and so we excluded it (<a href="./references#CD007302-bbs2-0013" title="ProvincialiL , BartoliniM , MariF , Del PesceM , CeravoloMG . Influence of vigabatrin on cognitive performances and behaviour in patients with drug-resistant epilepsy. Acta Neurologica Scandinavica1996;94:12-8. ">Provinciali 1996</a>). </p> </section> </section> <section id="CD007302-sec-0045"> <h3 class="title">Risk of bias in included studies</h3> <p>The risk of bias judgements for each study are presented in the 'Risk of bias' table located in the <a href="./references#CD007302-sec-0083" title="">Characteristics of included studies</a> table. <a href="#CD007302-fig-0002">Figure 2</a> provides an illustrative summary of the risk of bias judgements across all of the included studies, while <a href="#CD007302-fig-0003">Figure 3</a> is a graph displaying the proportion of studies awarded a high, unclear or low risk of bias judgement for each risk of bias domain. </p> <div class="figure" id="CD007302-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007302-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD007302-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007302-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD007302-sec-0046"> <h4 class="title">Allocation</h4> <p>Nine of the 11 included studies specifically reported that they were RCTs. However, only two studies described valid methods for random sequence generation (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>). Specifically, <a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a> used a computer‐generated randomisation schedule and <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a> used a random number generated code. Therefore, we both studies were at low risk of selection bias for random sequence generation. We rated six studies at unclear risk of bias for random sequence generation because they did not provide details of how randomisation was achieved (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>). In contrast, <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a> did describe a method of randomisation, however, we deemed the method of random sequence generation to be inadequate. <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a> randomised participants to treatment dependent on their order of enrolment on the study. This would produce a predictive randomisation pattern which personnel could then use to predict treatment allocation. Therefore, we judged that this study at high risk of selection bias due to random sequence generation. </p> <p>Two studies did not specify in the publication text whether they were randomised trials (<a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). However, we assumed that the two studies were randomised because both studies were described as being double‐blind. This would suggest that the personnel were not aware of treatment allocation, thus implying that randomisation had been conducted. For this reason, we continued to include the two studies in the review but awarded them high risk of bias for random sequence generation to convey our uncertainty. </p> <p>All 11 studies failed to provide any methods for allocation concealment (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). Consequently, we judged that all of the included studies were at unclear risk of selection bias for allocation concealment. </p> </section> <section id="CD007302-sec-0047"> <h4 class="title">Blinding</h4> <p>All 11 studies stated that placebo was either 'matched' or 'identical' in appearance (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>), with two trials masking for taste (<a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>). Therefore, we judged all 11 studies at low risk of performance bias. </p> <p>In contrast, none of the included studies reported whether, or how, outcome assessment was blinded. As a result, we deemed all 11 studies at unclear risk of detection bias. </p> </section> <section id="CD007302-sec-0048"> <h4 class="title">Incomplete outcome data</h4> <p>Three studies reported attrition and conducted an ITT analysis, although, on occasion, this was not specifically stated (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). Hence, these three studies were at low risk of attrition bias. <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> also conducted an ITT analysis and did report the overall attrition rate for the study, but did not specify the attrition rate per treatment group. Consequently, this study was at unclear risk of attrition bias. We also judged that <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a> was at unclear risk of attrition bias. Attrition was reported; however, it was not clear whether ITT analysis had been used. </p> <p>We judged that six other studies were at unclear risk of attrition bias (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a><a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>). The six studies fully reported attrition; however, did not conduct an ITT analysis. </p> </section> <section id="CD007302-sec-0049"> <h4 class="title">Selective reporting</h4> <p>Nine studies reported all outcomes that they had specified in the methods section of their full‐text publications in their respective results section (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). Therefore, these nine studies were at low risk of reporting bias. </p> <p>We judged that <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> was at unclear risk of reporting bias after the outcome treatment withdrawal was only partially reported. As alluded to earlier, <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> reported the total number of participants who withdrew from the study but did not specify the number of participants who withdrew per treatment group. Consequently, we were unable to use the include data from the study for the outcome, treatment withdrawal for any reason, and were also unable to complete an ITT analysis for the other outcomes, including 50% or greater reduction in seizure frequency. For this reason, the study was at unclear risk of reporting bias. </p> <p><a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a> specified no outcomes in the methods section of the publication text. As a result, we were unable to determine whether all intended outcomes had been reported. Therefore, we judged that <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a> was at unclear risk of reporting bias. </p> </section> <section id="CD007302-sec-0050"> <h4 class="title">Other potential sources of bias</h4> <p>Four trials were cross‐over designs without washout periods (<a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). As a consequence, there could have been a carryover effect between the two treatments that could have biased the results. Hence, we judged the four cross‐over studies at unclear risk of other bias. <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a> did exclude data collected during the first week of each treatment arm to compensate for not including a washout period. However, we considered that this time period was of inadequate length to avoid any carryover effect and, therefore, this study was at unclear risk of other bias. Another cross‐over study did not include a baseline period (<a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>). Without a baseline period to assess participants' basal seizure frequency, it was not possible to determine whether the severity of epilepsy was balanced between treatment groups. Consequently, this study was at unclear risk of other bias. </p> <p>We did not detect any other potential sources of bias for the other six included studies (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>). Therefore, these studies were at low risk of other bias. </p> </section> </section> <section id="CD007302-sec-0051"> <h3 class="title" id="CD007302-sec-0051">Effects of interventions</h3> <p>See: <a href="./full#CD007302-tbl-0001"><b>Summary of findings 1</b> Vigabatrin compared to placebo for drug‐resistant focal epilepsy</a> </p> <p>The main results of the review can be found in <a href="./full#CD007302-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD007302-sec-0052"> <h4 class="title">50% or greater reduction in seizure frequency</h4> <p>Four studies reported 50% or greater reduction in seizure frequency in accordance with the definition in the <a href="#CD007302-sec-0020">Types of outcome measures</a> subsection (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>). Specifically, we defined the outcome as the proportion of participants who experienced a 50% or greater reduction in seizure frequency during the treatment period when compared to the prerandomisation baseline period. Unfortunately, although the other seven included studies did report the outcome, the definition that the studies used did not adhere to our definition (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). In these studies, percentage seizure reduction was considered as the difference in seizure frequency during the vigabatrin treatment arm compared to the placebo treatment arm, rather than being compared against the seizure frequency during the baseline period. For this reason, we were unable to incorporate data from these seven studies into the meta‐analysis. </p> <p>The four studies that reported the outcome were all parallel‐group studies and included 513 participants (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>). The meta‐analysis pooling across doses (vigabatrin 1 g/day to 6 g/day) showed some evidence of heterogeneity (I<sup>2</sup> = 34% in the ITT analysis); however, according to our methods, this was not statistically significant. Thus, we utilised a fixed‐effect model. Participants allocated to vigabatrin were more likely to achieve a 50% or greater reduction in seizure frequency (RR 2.60, 95% CI 1.87 to 3.63; P &lt; 0.001; low‐certainty evidence; <a href="./references#CD007302-fig-0004" title="">Analysis 1.1</a>). </p> <p>For the best‐case scenario, there was no significant heterogeneity, therefore, we continued to utilise a fixed‐effect model for the analysis. The best‐case analysis indicated that participants allocated to vigabatrin were nearly three times as likely to achieve a 50% or greater reduction in seizure frequency than those allocated to placebo (RR 2.78, 95% CI 2.02 to 3.82; I<sup>2</sup> = 0%; <a href="./references#CD007302-fig-0005" title="">Analysis 1.2</a>). In contrast, there was significant heterogeneity within the worst‐case analysis data set so we employed a random‐effects model (I<sup>2</sup> = 61%). The worst‐case scenario demonstrated that participants allocated to vigabatrin remained more likely to achieve a 50% or greater reduction in seizure frequency than those allocated to placebo (RR 1.65, 95% CI 0.98 to 2.76; <a href="./references#CD007302-fig-0006" title="">Analysis 1.3</a>); however, the effect size calculated was not statistically significant (P = 0.06). We then conducted a sensitivity analysis to investigate whether the use of a random‐effects model over a fixed‐effect model influenced the findings. The sensitivity analysis revealed little difference in the overall RR calculated (RR 1.61, 95% CI 1.20 to 2.16), but did result in the effect size calculated becoming statistically significant (P = 0.001). </p> <p>We were unable to construct a funnel plot for this outcome as too few studies reported the outcome according to our definition of 50% or greater seizure reduction. Therefore, we were unable to comment on whether there was reporting bias towards smaller studies. </p> </section> <section id="CD007302-sec-0053"> <h4 class="title">Treatment withdrawal for any reason</h4> <p>Four trials reported sufficient information to calculate the number of participants withdrawing from each treatment arm (<a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). The four studies consisted of 370 individual participants. Notably, <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a> was a cross‐over study so data from the 31 included participants was included in both treatment groups for the purposes of our current meta‐analysis. All other included studies reported total numbers of participants withdrawing from treatment but did not provide sufficient information for us to calculate which treatment arm these participants had belonged to at the time of treatment withdrawal (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>). </p> <p>An analysis pooling across doses showed evidence of no heterogeneity between the four studies for which data on withdrawal by treatment group were presented (I<sup>2</sup> = 0%). Therefore, we used a fixed‐effect model. Participants allocated to vigabatrin were nearly three times more likely to have treatment withdrawn for any reason compared to those taking placebo (RR 2.86, 95% CI 1.25 to 6.55; P = 0.01; very low‐certainty evidence; <a href="./references#CD007302-fig-0007" title="">Analysis 1.4</a>). </p> </section> <section id="CD007302-sec-0054"> <h4 class="title">Adverse effects</h4> <p>All 11 included studies (756 participants) reported adverse effects data. The data included more participants with non‐focal epilepsy than did the analysis of the primary outcome above. This was because, although seizure reduction data were reported by the individual or by seizure type, adverse effect data were not. Although the vast majority of participants had focal epilepsy, several studies included some participants with other seizure types (<a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>: four; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>: two; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>: number with non‐focal type unclear; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>: three; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>: one). In addition, due to the way in which the data were reported, the denominators for the adverse effect data sometimes differed slightly to the number in each treatment arm (<a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>), although these discrepancies were small (one in both cases). </p> <p>An analysis pooling data from all trials showed no heterogeneity for any of the 10 adverse effects considered (I<sup>2</sup> statistics ranged from 0% to 50%). The data set for one adverse event, nystagmus, did display some heterogeneity (I<sup>2</sup> = 49%); however, according to our stated methods, this level of heterogeneity did not reach the threshold at which we would consider using a random‐effects model (i.e. I<sup>2</sup> &gt; 50%). Therefore, we employed a fixed‐effect model for all 10 adverse effects outcomes assessed. </p> <p>The analyses pooling data across doses indicated that the following adverse effects were significantly associated with vigabatrin: dizziness/light‐headedness (RR 1.74, 99% CI 1.05 to 2.87; 9 studies; 709 participants; low‐certainty evidence; <a href="./references#CD007302-fig-0009" title="">Analysis 1.6</a>), fatigue (RR 1.65, 99% CI 1.08 to 2.51; 9 studies; 709 participants; low‐certainty evidence; <a href="./references#CD007302-fig-0010" title="">Analysis 1.7</a>), drowsiness (RR 1.70, 99% CI 1.18 to 2.44; 8 studies; 666 participants; <a href="./references#CD007302-fig-0011" title="">Analysis 1.8</a>), and depression (RR 3.28, 99% CI 1.30 to 8.27; 6 studies; 546 participants; <a href="./references#CD007302-fig-0013" title="">Analysis 1.10</a>). Although we observed increased incidence rates in the vigabatrin group compared to placebo for: ataxia (RR 2.76, 99% CI 0.96 to 7.94; 7 studies; 481 participants; very low‐certainty evidence; <a href="./references#CD007302-fig-0008" title="">Analysis 1.5</a>), nausea (RR 3.57, 99% CI 0.63 to 20.30; 4 studies; 251 participants; <a href="./references#CD007302-fig-0012" title="">Analysis 1.9</a>), headache (RR 1.23, 99% CI 0.79 to 1.92; 9 studies; 709 participants; <a href="./references#CD007302-fig-0014" title="">Analysis 1.11</a>), abnormal vision (RR 1.64, 99% CI 0.67 to 4.02; 5 studies; 430 participants; very low‐certainty evidence; <a href="./references#CD007302-fig-0015" title="">Analysis 1.12</a>), diplopia (RR 1.76, 99% CI 0.94 to 3.30; 7 studies, 655 participants; <a href="./references#CD007302-fig-0016" title="">Analysis 1.13</a>), and nystagmus (RR 1.53, 99% CI 0.62 to 3.76; 2 studies; 357 participants; low‐certainty evidence; <a href="./references#CD007302-fig-0017" title="">Analysis 1.14</a>); these overall effect sizes were not statistically significant. Notably, fewer than half of the studies recorded any occurrences of abnormal vision, diplopia or nystagmus. </p> </section> <section id="CD007302-sec-0055"> <h4 class="title">Dose‐response analysis</h4> <p>Six trials randomised participants to placebo or vigabatrin 3 g/day (<a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>; <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0006" title="GrunewaldRA , ThompsonPJ , CorcoranR , CordenZ , JacksonGD , DuncanJS . Effects of vigabatrin on partial seizures and cognitive function. Journal of Neurology, Neurosurgery, and Psychiatry1994;57:1057-63. ">Grunewald 1994</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>; <a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>), two trials randomised participants to either 2 g/day or 3 g/day depending on bodyweight (<a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>), and <a href="./references#CD007302-bbs2-0002" title="BruniJ , GubermanA , VachonL , DesforgesC . Vigabatrin as add-on therapy for adult complex partial seizures: a double-blind, placebo-controlled multicentre study. The Canadian Vigabatrin Study Group. Seizure2000;9:224-32. ">Bruni 2000</a> titrated to maximum doses of 4 g/day. </p> <p>Two trials examined response rates over different doses of vigabatrin. <a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a> compared percentage reduction in mean back‐transformed seizure rate between vigabatrin 2 g/day and 3 g/day, relative to placebo. The study demonstrated a 36% reduction in mean back‐transformed seizure rate with 2 g/day versus 31% reduction with 3 g/day. There were no significant differences in seizure reduction between doses. <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> compared response rates between placebo, and vigabatrin 1 g/day, 3 g/day and 6 g/day. The proportion of participants achieving a 50% or greater reduction in seizure frequency were: placebo: 7%; 1 g/day: 24%; 3 g/day: 51% and 6 g/day: 53%. The difference between 6 g/day and 3 g/day was not significant. </p> </section> <section id="CD007302-sec-0056"> <h4 class="title">Cognitive outcomes and quality of life</h4> <p>Two trials evaluated cognitive and quality of life outcomes (<a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>), while one study reported only cognitive outcomes (<a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>). <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> (174 participants) and <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a> (183 participants) were both large multicentre trials, whereas <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a> was a small cross‐over study with 24 participants. </p> <p>The two larger trials included the same eight cognitive tests of abilities (Lafayette Grooved Pegboard, Stroop Test, Benton Visual Retention Test, Controlled Oral Word Association Test, Symbol Digit Modalities Test, Rey Auditory Verbal Learning Test, Wonderlic Personnel Test and the Digit Cancellation Test), and the same three mood tests (Profile of Mood States, Washington Psychosocial Seizure Inventory and Mood Rating Scale) (<a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a>; <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>). There were no differences between the placebo and vigabatrin groups at the end of the study for any of the eight tested outcomes for <a href="./references#CD007302-bbs2-0004" title="DodrillCB , ArnettJL , SommervilleKW , SussmanNM . Evaluation of the effects of vigabatrin on cognitive abilities and quality of life in epilepsy. Neurology1993;43:2501-7. FrenchJA , MosierM , WalkerS , SommervilleK , SussmanN . A double-blind, placebo-controlled study of vigabatrin three g/day in patients with uncontrolled complex partial seizures. Neurology1996;46:54-61. ">French 1996</a>, whereas <a href="./references#CD007302-bbs2-0003" title="DeanC , MosierM , PenryK . Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia1999;40:74-82. DodrillCB , ArnettJL , SommervilleKW , SussmanNW . Effects of differing dosages of vigabatrin (Sabril) on cognitive abilities and quality of life in epilepsy. Epilepsia1995;36(2):164-73. ">Dean 1999</a> reported outcomes from the Digit Cancellation Test decreased with increasing doses of the drug. In summary, vigabatrin had little impact on tests of cognitive abilities or quality of life. </p> <p><a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a> employed an assortment of three psychomotor test, four memory tests (Forward Digit Span Test, Backward Digit Span Test, Paired Associate Learning Test and Rivermead Behavioural Memory Test) and three self‐reported rating scales to assess cognition. Similarly, this study found no significant differences in test or scale scores between participants who received vigabatrin or placebo at any time point. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007302-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007302-sec-0057"></div> <section id="CD007302-sec-0058"> <h3 class="title" id="CD007302-sec-0058">Summary of main results</h3> <p>This systematic review and meta‐analysis of short‐term RCTs of vigabatrin suggests that vigabatrin may be effective in reducing seizure frequency in drug‐resistant focal epilepsy, at least in the short term. Specifically, people with drug‐resistant focal epilepsy who are given vigabatrin may be two to three times more likely to achieve a 50% or greater reduction in seizure frequency compared to those given placebo. </p> <p>In addition reducing seizure frequency, an AED needs to have good tolerability, with limited adverse effects. Overall, tolerability can be measured by the proportion of participants withdrawing from treatment and incidence rates of adverse effects reported while taking the drug. In this review, we demonstrated that several of the investigated adverse effects may be significantly associated with vigabatrin, such as dizziness/light‐headedness, fatigue, drowsiness and depression. Furthermore, the evidence also suggested that participants may be up to three times more likely to withdraw from treatment with vigabatrin compared to placebo. Interestingly, none of the three visual adverse effects were associated with vigabatrin compared to placebo. However, this is not surprising given the short duration of the included studies. </p> </section> <section id="CD007302-sec-0059"> <h3 class="title" id="CD007302-sec-0059">Overall completeness and applicability of evidence</h3> <p>This review only synthesised evidence from trials comparing vigabatrin to placebo and did not compare vigabatrin to other AEDs. Furthermore, and perhaps more importantly, it does not inform us of how frequently constriction of the visual field occurs. Although vigabatrin may have proven efficacy in reducing seizures, associated adverse effects (visual field constrictions) are common and can be severe (<a href="./references#CD007302-bbs2-0031" title="NicolsonA , LeachJP , ChadwickCW , SmithDF . The legacy of vigabatrin in a regional epilepsy clinic. Journal of Neurology, Neurosurgery, and Psychiatry2002;73:327-9.">Nicolson 2002</a>). From assessing three visual adverse effects that we knew could be detected within a short‐term follow‐up period, we found that none were significantly associated with vigabatrin treatment compared to placebo. It is important to consider that such visual defects may not have been detected due to the short treatment durations and follow‐ups of the included studies. Long‐term observational studies may provide a more accurate representation of the adverse effect profile of vigabatrin. </p> <p>Moreover, this review cannot inform readers about the efficacy or tolerability of vigabatrin in children. Two studies enrolled populations aged 10 to 58 years. However, the majority of the other studies enrolled people aged 17 or 18 and older. From this perspective, the findings of this review may not be applicable to children. Separate studies should be completed in order to confirm this. </p> </section> <section id="CD007302-sec-0060"> <h3 class="title" id="CD007302-sec-0060">Certainty of the evidence</h3> <p>We evaluated that all of the included studies demonstrated unclear risk of bias across at least three risk of bias domains. For this reason, we downgraded the evidence for all GRADE‐assessed outcomes once for risk of bias (see <a href="./full#CD007302-tbl-0001">summary of findings Table 1</a>). We also noted imprecision in the results due to the low number of events recorded. For three outcomes (50% or greater reduction in seizure frequency, dizziness/light‐headedness, fatigue, and nystagmus), there were between 100 and 400 events across the treatment groups. The low number of events did not satisfy the suggested optimal information size, therefore, we downgraded the evidence for these outcomes once. This resulted in a GRADE assessment of low‐certainty evidence for the three outcomes. Moreover, there were fewer than 100 events across treatment groups for the remaining three outcomes (treatment withdrawal due to any reason, ataxia, and abnormal vision). Due to the very limited number of events, we downgraded the evidence for these outcomes twice. Consequently, we assessed the evidence for the remaining four outcomes as very low‐certainty. </p> </section> <section id="CD007302-sec-0061"> <h3 class="title" id="CD007302-sec-0061">Potential biases in the review process</h3> <p>Two of the seven cross‐over trials incorporated formal washout periods within the trial design (<a href="./references#CD007302-bbs2-0001" title="BeranRG , BerkovicSF , BuchananN , DantaG , MackenzieR , SchapelG , et al. A double-blind, placebo-controlled crossover study of vigabatrin 2 g/day and 3 g/day in uncontrolled partial seizures. Seizure1996;5:259-65. ">Beran 1996</a>; <a href="./references#CD007302-bbs2-0008" title="GilhamRA , BlacklawJ , McKeePJ , BrodieMJ . Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy. Journal of Neurology1993;56:1271-5. McKeePJ , BlacklawJ , FrielE , ThompsonGG , GillhamRA , BrodieMJ . Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients?Epilepsia1993;34(5):937-43. ">McKee 1993</a>), and three trials added single‐blind placebo periods to the end of the study to test for carry‐over effects (<a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a>; <a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>), which were not significant in two trials (<a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). Two trials excluded part of the treatment period from the analysis to incorporate a washout period (<a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a> excluded one treatment week and <a href="./references#CD007302-bbs2-0005" title="GramL , KlosterskovP , DamM . Gamma-vinyl GABA: a double-blind placebo-controlled trial in partial epilepsy. Annals of Neurology1985;17:262-6. ">Gram 1985</a> excluded four weeks). Two of the seven cross‐over trials had no washout period (<a href="./references#CD007302-bbs2-0009" title="RimmerEM , RichensA . Double-blind study of gamma-vinyl GABA in patients with refractory epilepsy. Lancet1984;1(8370):189-90. ">Rimmer 1984</a>; <a href="./references#CD007302-bbs2-0010" title="TartaraA , ManniR , GalimbertiCA , HardenbergJ , OrwinJ , PeruccaE . Vigabatrin in the treatment of epilepsy: a double blind, placebo controlled study. Epilepsia1986;27:717-23. ">Tartara 1986</a>). Analysis here assumed that there was no carry‐over effect of vigabatrin when participants crossed from vigabatrin to placebo. There is some evidence to support this assumption (<a href="./references#CD007302-bbs2-0007" title="LoiseauP , HardenbergJP , PestreM , GuyotM , SchechterPJ , TellGP . Double blind, placebo controlled study of vigabatrin (gamma vinyl GABA) in drug resistant epilepsy. Epilepsia1986;27:115-20. ">Loiseau 1986</a>; <a href="./references#CD007302-bbs2-0011" title="TassinariCA , MichelucciR , AmbrosettoG , SalviF . Double blind study of vigabatrin in the treatment of drug resistant epilepsy. Archives of Neurology1987;44:907-10. ">Tassinari 1987</a>). A sensitivity analysis excluding trials first with no washout period and then excluding all cross‐over trials revealed no systematic departures in overall conclusions. </p> <p>The review might also present slightly skewed results regarding the adverse effect profile associated with short‐term vigabatrin due to the inclusion of data from participants with seizure types other than focal seizures. However, the vast majority of data were collected from participants with drug‐resistant focal epilepsy, so any impact from the inclusion of participants with any other seizure type should be minimal. </p> </section> <section id="CD007302-sec-0062"> <h3 class="title" id="CD007302-sec-0062">Agreements and disagreements with other studies or reviews</h3> <p>An analysis of short‐term RCTs, such as the analysis presented here, cannot detect adverse effects that take longer (compared to the length of an RCT) to develop or present, or adverse effects that are very rare. Longer‐term observational studies of vigabatrin have identified that visual field defects are a common adverse effect associated with the prolonged use of vigabatrin (<a href="./references#CD007302-bbs2-0031" title="NicolsonA , LeachJP , ChadwickCW , SmithDF . The legacy of vigabatrin in a regional epilepsy clinic. Journal of Neurology, Neurosurgery, and Psychiatry2002;73:327-9.">Nicolson 2002</a>; <a href="./references#CD007302-bbs2-0037" title="WildJM , AhnHS , BaulacM , BursztrynJ , ChrionC , GandolfoE , et al. Vigabatrin and epilepsy: lessons learned. Epilepsia2007;48:1318-27.">Wild 2007</a>). This important adverse effect has been observed in both adults and children, and the incidence rate increases with increased dose and with longer duration of use (<a href="./references#CD007302-bbs2-0037" title="WildJM , AhnHS , BaulacM , BursztrynJ , ChrionC , GandolfoE , et al. Vigabatrin and epilepsy: lessons learned. Epilepsia2007;48:1318-27.">Wild 2007</a>). The associated visual field defects are, however, often asymptomatic. As a result, this adverse effect would most likely not be detected by RCTs. </p> <p>In this systematic review, we included three visual adverse effects, any abnormality of vision, diplopia and nystagmus. It cannot be assumed that summary statistics produced by a systematic review of RCTs will provide an adequate representation of associated visual field defects; in fact, they are expected to underestimate true risks. An analysis of the extent of visual field defects associated with vigabatrin use is the subject of another systematic review which has shown that an estimated 44% of participants exposed to vigabatrin develop visual field loss (<a href="./references#CD007302-bbs2-0029" title="MaguireMJ , HemmingK , WildJM , HuttonJL , MarsonAG . Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review. Epilepsia2010;51(12):2423-31. [DOI: 10.1111/j.1528-1167.2010.02772]">Maguire 2010</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007302-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007302-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD007302-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD007302-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 1: 50% or greater reduction in seizure frequency (ITT analysis)" data-id="CD007302-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 1: 50% or greater reduction in seizure frequency (ITT analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 2: 50% or greater reduction in seizure frequency (best‐case analysis)" data-id="CD007302-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 2: 50% or greater reduction in seizure frequency (best‐case analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 3: 50% or greater reduction in seizure frequency (worst‐case analysis)" data-id="CD007302-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 3: 50% or greater reduction in seizure frequency (worst‐case analysis) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 4: Treatment withdrawal due to any reason" data-id="CD007302-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 4: Treatment withdrawal due to any reason </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 5: Ataxia" data-id="CD007302-fig-0008" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 5: Ataxia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 6: Dizziness/light‐headedness" data-id="CD007302-fig-0009" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 6: Dizziness/light‐headedness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 7: Fatigue" data-id="CD007302-fig-0010" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 7: Fatigue</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 8: Drowsiness" data-id="CD007302-fig-0011" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 8: Drowsiness</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 9: Nausea" data-id="CD007302-fig-0012" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 9: Nausea</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 10: Depression" data-id="CD007302-fig-0013" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 10: Depression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 11: Headache" data-id="CD007302-fig-0014" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 11: Headache</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.12" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 12: Abnormal vision" data-id="CD007302-fig-0015" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.12.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 12: Abnormal vision</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.12.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.13" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 13: Diplopia" data-id="CD007302-fig-0016" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.13.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 13: Diplopia</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.13.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007302-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/urn:x-wiley:14651858:media:CD007302:CD007302-CMP-001.14" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Vigabatrin versus placebo, Outcome 14: Nystagmus" data-id="CD007302-fig-0017" src="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.14.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_t/tCD007302-CMP-001.14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1: Vigabatrin versus placebo, Outcome 14: Nystagmus</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/media/CDSR/CD007302/image_n/nCD007302-CMP-001.14.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007302-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vigabatrin compared to placebo for drug‐resistant focal epilepsy</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Vigabatrin compared to placebo for drug‐resistant focal epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people (aged 10–64 years) with drug‐resistant focal epilepsy </p> <p><b>Setting:</b> outpatients </p> <p><b>Intervention:</b> vigabatrin (doses used: 2 g/day, 3 g/day, 1–4 g/day, 6 g/day) </p> <p><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects* (95% CI, 99% CI for adverse effect outcomes)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI, 99% CI for adverse effect outcomes)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with vigabatrin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>≥ <b>50% reduction in seizure frequency (ITT analysis)</b> </p> <p>Duration of treatment (range): 16–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.60</b><br/>(1.87 to 3.63) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>513</b><br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The other 7 studies did report the outcome; however, the data were not usable. The studies compared seizure frequency with vigabatrin to the placebo treatment period rather than the baseline period, as per our definition. </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>180 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>468 per 1000<br/>(337 to 654) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment withdrawal for any reason</b> </p> <p>Duration of treatment (range): 12 (3 months) to 36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.86</b><br/>(1.25 to 6.55) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>370</b><br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>87 per 1000<br/>(38 to 199) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: ataxia</b> </p> <p>Duration of treatment (range): 7–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 2.76</b><br/>(0.96 to 7.94) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>481</b><br/>(7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>14 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>38 per 1000<br/>(13 to 108) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: dizziness/light‐headedness</b> </p> <p>Duration of treatment (range): 7–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.74</b><br/>(1.05 to 2.87) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>709</b><br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>84 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>145 per 1000<br/>(88 to 240) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: fatigue</b> </p> <p>Duration of treatment (range): 8–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.65</b><br/>(1.08 to 2.51) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>709</b><br/>(9 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>113 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>186 per 1000<br/>(122 to 284) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: nystagmus</b> </p> <p>Duration of treatment (range): 16–18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.53</b><br/>(0.62 to 3.76) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>357</b><br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>L<b>ow</b><sup>a,b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>89 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>136 per 1000<br/>(55 to 334) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse effects: abnormal vision</b> </p> <p>Duration of treatment (range): 8–36 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Study population</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 1.64</b><br/>(0.67 to 4.02) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>430</b><br/>(5 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>a,c</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>45 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>74 per 1000<br/>(30 to 182) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>ITT:</b> intention‐to‐treat; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded one level for risk of bias. We judged all included studies at unclear risk of bias for allocation concealment and blinding of outcome assessment. Furthermore, we assessed most studies at unclear risk of selection bias and attrition bias with three studies displaying high risk of selection bias.<br/><sup>b</sup>Downgraded one level for imprecision: the number of events (fewer than 400) did not satisfy the optimal information size.<br/><sup>c</sup>Downgraded two levels for imprecision: the number of events (fewer than 100) did not satisfy the optimal information size. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Vigabatrin compared to placebo for drug‐resistant focal epilepsy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/full#CD007302-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007302-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vigabatrin versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 50% or greater reduction in seizure frequency (ITT analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>513</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.60 [1.87, 3.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 50% or greater reduction in seizure frequency (best‐case analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [2.02, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 50% or greater reduction in seizure frequency (worst‐case analysis) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>339</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [0.98, 2.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Treatment withdrawal due to any reason <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>401</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.86 [1.25, 6.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Ataxia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [0.96, 7.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Dizziness/light‐headedness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.74 [1.05, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.65 [1.08, 2.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Drowsiness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.70 [1.18, 2.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>328</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.57 [0.63, 20.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.10 Depression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>690</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.28 [1.30, 8.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.11 Headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>905</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.79, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.12 Abnormal vision <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.64 [0.67, 4.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.13 Diplopia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.76 [0.94, 3.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.14 Nystagmus <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 99% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.53 [0.62, 3.76]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Vigabatrin versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007302.pub3/references#CD007302-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007302.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007302-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007302-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007302-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD007302-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007302-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007302-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD007302-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007302-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007302\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007302\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007302\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007302\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007302\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=IregKd2C&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007302.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007302.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007302.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007302.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007302.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740729323974"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007302.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740729323977"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007302.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918eda1cea62f4a4',t:'MTc0MDcyOTMyNC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 